Posted inGenetics
New Subtypes of Major Neurons Involved in the Hearing Process Identified
Scientists at the Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and…
Posted inBiotechnology
Chutes & Ladders—Amylyx preps for GLP-1 launch with new CCO
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…
Posted inMedical Technology
Insilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M deal
Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group. Following a licensing agreement last…
Posted inBiotechnology
Light Horse lassos Novartis partnership worth up to $1B, wrangles $62M series A
Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis…
Posted inBiotechnology
GSK-backed Ouro Medicines launches into T-cell engager space with $115M and a clinical-stage asset
Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager (TCE)…
Posted inBiotechnology
Moderna co-founder Chien’s new biotech inks $950M RNA deal with Etherna
Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.…
Posted inMedical Technology
Illumina rolls out single-cell & single-flow cell kits for low-volume labs
Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making…
Posted inGenetics
New Prime Editing System, mvGPT, Combines Editing and Regulation
A new genome editing tool—minimal versatile genetic perturbation technology (mvGPT)—can achieve simultaneous and orthogonal gene editing and gene regulation in…
Posted inMedical Technology
Vensana Capital keeps up momentum with third medtech investment fund, raising $425M
The venture firm Vensana Capital has raised its third medtech-focused fund in the past six years, with $425 million in…
Posted inBiotechnology
After rejection, Vanda CEO pens searing letter to FDA commissioner about ‘disturbing pattern of conduct’
After Vanda Pharmaceuticals’ phase 3 miss and FDA rejection for its stomach disorder candidate, CEO Mihael Polymeropoulos, M.D., is calling…